Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 54,453 shares, a decline of 38.9% from the June 30th total of 89,082 shares. Based on an average daily volume of 45,733 shares, the short-interest ratio is presently 1.2 days. Currently, 0.1% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Estrella Immunopharma presently has an average rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Down 4.4%

Shares of ESLA stock traded down $0.03 during trading hours on Thursday, hitting $0.74. 26,234 shares of the company’s stock were exchanged, compared to its average volume of 116,042. The firm has a market cap of $32.06 million, a P/E ratio of -2.19 and a beta of 0.85. The firm has a 50 day moving average of $0.98 and a two-hundred day moving average of $1.16. Estrella Immunopharma has a fifty-two week low of $0.69 and a fifty-two week high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Saturday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. On average, equities analysts forecast that Estrella Immunopharma will post -0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd increased its stake in Estrella Immunopharma by 376.9% during the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after buying an additional 39,099 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Estrella Immunopharma during the fourth quarter worth approximately $43,000. Marshall Wace LLP acquired a new position in Estrella Immunopharma in the 4th quarter valued at $88,000. State Street Corp lifted its holdings in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after purchasing an additional 20,900 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Estrella Immunopharma by 1,045.7% during the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after purchasing an additional 111,779 shares during the last quarter. 0.35% of the stock is owned by hedge funds and other institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.